Last updated: February 27, 2026
What is NDC 65862-0940?
NDC 65862-0940 refers to Clostridium botulinum toxin type A, marketed as Daxxify (formerly known as daxibotulinumtoxinA-lanm), indicated primarily for aesthetic purposes, such as wrinkle reduction. Its approval status, competitive positioning, and pricing are key factors influencing market prospects.
Market Overview
Therapeutic Area
- Indications: Primarily aesthetic treatment for glabellar lines.
- Market Size (Aesthetic Botulinum Toxin): Globally, the botulinum toxin market was valued at USD 4.9 billion in 2022, with an expected CAGR of 8% through 2030. The aesthetic segment accounts for roughly 70% of this value.
Competitive Landscape
| Product |
Company |
Approval Date |
Primary Use |
Duration of Effect |
Pricing (USD per vial) |
Market Share (2022) |
| Botox (onabotulinumtoxinA) |
Allergan (AbbVie) |
1989 |
Aesthetic, therapeutic |
3-4 months |
500-700 |
50% |
| Dysport (abobotulinumtoxinA) |
Ipsen |
2009 |
Aesthetic, therapeutic |
3-4 months |
400-600 |
20% |
| Xeomin (incobotulinumtoxinA) |
Merz |
2011 |
Aesthetic, therapeutic |
3-4 months |
400-600 |
10% |
| Daxxify (daxibotulinumtoxinA-lanm) |
Revance |
2022 |
Aesthetic (FDA approval) |
Up to 6 months |
800-1000 |
<10% (initial) |
Regulatory Status
- FDA approval: 2022 for aesthetic use.
- EMA and other agencies: Under review or pending approvals.
Market Entry Implications
- Daxxify’s longer durability could provide competitive advantage.
- Early market share is expected to remain limited due to the established presence of Botox and competitors.
Price Projection Analysis
Current Pricing
- Daxxify’s per vial price ranges from USD 800 to 1,000.
- Initial pricing aligns with premium injectables with longer effect durations.
Price Trends and Forecasts (2023–2030)
| Year |
Projected Price Range (USD per vial) |
Key Assumptions |
| 2023 |
850 - 1,000 |
Launch phase, premium pricing maintained |
| 2025 |
800 - 950 |
Competitive response, slight price erosion |
| 2027 |
750 - 900 |
Market penetration increases, price stabilization |
| 2030 |
700 - 850 |
Competitive pressures, volume-based discounts |
Factors Influencing Price Dynamics
- Market penetration: Slower uptake may increase per-vial prices initially.
- Competitor actions: Price cuts by Botox or Dysport could pressure Daxxify’s pricing.
- Reimbursement policies: Insurance coverage for aesthetic procedures remains limited, affecting consumer-initiated demand.
- Manufacturing costs: Stable or decreasing due to improved production efficiency.
Volume and Revenue Projections
- Assuming a conservative 10% annual increase in market share.
- Average price remaining near USD 900 initially, decreasing to USD 750 by 2030.
- Revenue estimates (initial):
| Year |
Units Sold (millions) |
Revenue (USD billions) |
| 2023 |
1.0 |
0.9 |
| 2025 |
2.0 |
1.5 |
| 2030 |
3.5 |
2.6 |
Risks and Opportunities
Risks
- Entrenched competition from Botox, Dysport, Xeomin.
- Regulatory delays or restrictions.
- Cost containment measures limiting pricing power.
- Limited insurance reimbursement, constraining growth.
Opportunities
- Longer-acting profile appeals to patients desiring fewer injections.
- Potential expansion into therapeutic indications (e.g., dystonia).
- Geographic expansion into emerging markets with rising aesthetic demand.
Key Takeaways
- Daxxify entered a highly competitive, mature market with established products.
- Its longer duration (~6 months) enables premium pricing (~USD 800–1,000/vial).
- Market share growth depends on acceptance, efficacy, and competitive responses.
- Price projections suggest gradual decline driven by increased volume and competition.
- Revenue growth hinges on adoption rate, geographic expansion, and reimbursement landscape.
FAQs
1. Will Daxxify’s longer duration justify higher prices?
Yes. Longer-lasting effects allow premium pricing, particularly at launch. Over time, competitive factors could pressure prices downward.
2. How does Daxxify’s market potential compare to Botox?
Daxxify provides a differentiated profile with longer duration. However, its initial small share limits immediate revenue potential relative to Botox, which dominates the market.
3. Are reimbursement policies favorable for new botulinum toxins?
Reimbursement remains limited for aesthetic uses. Therapeutic indications receive more support. Market growth relies on patient acceptance and provider willingness.
4. What geographic markets hold the most promise for Daxxify?
North America and Europe are primary. Emerging markets could expand growth, contingent on regulatory approvals and affordability.
5. How might pricing evolve if competition intensifies?
Prices may decline to retain market share, potentially stabilizing around USD 700–750/vial by 2030, emphasizing volume over premium pricing.
References
[1] MarketWatch. (2023). Global Botulinum Toxin Market Size, Share & Trends. Available at: https://www.marketwatch.com/
[2] Grand View Research. (2023). Botulinum Toxin Market Size, Share & Trends.
[3] U.S. Food and Drug Administration. (2022). FDA approves Daxxify for aesthetic use.
[4] Statista. (2023). Aesthetic botulinum toxin market revenue forecast.
[5] Revance. (2022). Daxxify FDA approval press release.
